Zions Bancorporation National Association UT Takes $980,000 Position in ADMA Biologics Inc $ADMA

Zions Bancorporation National Association UT purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 53,817 shares of the biotechnology company’s stock, valued at approximately $980,000.

Several other hedge funds have also recently added to or reduced their stakes in ADMA. Skandinaviska Enskilda Banken AB publ purchased a new position in ADMA Biologics in the 1st quarter valued at $35,000. SVB Wealth LLC acquired a new stake in shares of ADMA Biologics in the first quarter valued at about $35,000. Cullen Frost Bankers Inc. raised its position in shares of ADMA Biologics by 112.5% in the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,081 shares during the last quarter. Toth Financial Advisory Corp lifted its stake in shares of ADMA Biologics by 1,081.6% in the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock worth $46,000 after buying an additional 2,293 shares in the last quarter. Finally, Ameritas Advisory Services LLC acquired a new position in ADMA Biologics during the second quarter worth about $46,000. 75.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Stock Up 3.5%

NASDAQ ADMA opened at $14.52 on Monday. The business’s fifty day simple moving average is $15.37 and its 200-day simple moving average is $17.83. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.46 billion, a PE ratio of 16.88 and a beta of 0.40. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. During the same quarter in the prior year, the firm posted $0.15 earnings per share. ADMA Biologics’s quarterly revenue was up 12.0% on a year-over-year basis. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.